Outcomes for COPD pharmacological trials: From lung function to biomarkers

M. Cazzola; W. MacNee; F. J. Martinez; K. F. Rabe; L. G. Franciosi; P. J. Barnes; V. Brusasco; P. S. Burge; P. M.A. Calverley; B. R. Celli; P. W. Jones; D. A. Mahler; B. Make; M. Miravitlles; C. P. Page; P. Palange; D. Parr; M. Pistolesi; S. I. Rennard; M. P. Rutten-van Mölken; R. Stockley; S. D. Sullivan; J. A. Wedzicha; E. F. Wouters

doi:10.1183/09031936.00099306

Outcomes for COPD pharmacological trials: From lung function to biomarkers

M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M.A. Calverley, B. R. Celli, P. W. Jones, D. A. Mahler, B. Make, M. Miravitlles, C. P. Page, P. Palange, D. Parr, M. Pistolesi, S. I. Rennard, M. P. Rutten-van MölkenR. Stockley, S. D. Sullivan, J. A. Wedzicha, E. F. Wouters

Pulmonary, Critical Care, & Sleep Medicine

Research output: Contribution to journal › Review article › peer-review

741 Scopus citations

Abstract

The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

Original language	English (US)
Pages (from-to)	416-468
Number of pages	53
Journal	European Respiratory Journal
Volume	31
Issue number	2
DOIs	https://doi.org/10.1183/09031936.00099306
State	Published - Feb 2008

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/09031936.00099306

Cite this

Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., Jones, P. W., Mahler, D. A., Make, B., Miravitlles, M., Page, C. P., Palange, P., Parr, D., Pistolesi, M., Rennard, S. I., ... Wouters, E. F. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. European Respiratory Journal, 31(2), 416-468. https://doi.org/10.1183/09031936.00099306

Cazzola, M, MacNee, W, Martinez, FJ, Rabe, KF, Franciosi, LG, Barnes, PJ, Brusasco, V, Burge, PS, Calverley, PMA, Celli, BR, Jones, PW, Mahler, DA, Make, B, Miravitlles, M, Page, CP, Palange, P, Parr, D, Pistolesi, M, Rennard, SI, Rutten-van Mölken, MP, Stockley, R, Sullivan, SD, Wedzicha, JA & Wouters, EF 2008, 'Outcomes for COPD pharmacological trials: From lung function to biomarkers', European Respiratory Journal, vol. 31, no. 2, pp. 416-468. https://doi.org/10.1183/09031936.00099306

@article{5289b1ca463f437facdd57b9797470de,

title = "Outcomes for COPD pharmacological trials: From lung function to biomarkers",

abstract = "The American Thoracic Society/European Respiratory Society jointly created a Task Force on {"}Outcomes for COPD pharmacological trials: from lung function to biomarkers{"} to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright",

author = "M. Cazzola and W. MacNee and Martinez, {F. J.} and Rabe, {K. F.} and Franciosi, {L. G.} and Barnes, {P. J.} and V. Brusasco and Burge, {P. S.} and Calverley, {P. M.A.} and Celli, {B. R.} and Jones, {P. W.} and Mahler, {D. A.} and B. Make and M. Miravitlles and Page, {C. P.} and P. Palange and D. Parr and M. Pistolesi and Rennard, {S. I.} and {Rutten-van M{\"o}lken}, {M. P.} and R. Stockley and Sullivan, {S. D.} and Wedzicha, {J. A.} and Wouters, {E. F.}",

year = "2008",

month = feb,

doi = "10.1183/09031936.00099306",

language = "English (US)",

volume = "31",

pages = "416--468",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - Outcomes for COPD pharmacological trials

T2 - From lung function to biomarkers

AU - Cazzola, M.

AU - MacNee, W.

AU - Martinez, F. J.

AU - Rabe, K. F.

AU - Franciosi, L. G.

AU - Barnes, P. J.

AU - Brusasco, V.

AU - Burge, P. S.

AU - Calverley, P. M.A.

AU - Celli, B. R.

AU - Jones, P. W.

AU - Mahler, D. A.

AU - Make, B.

AU - Miravitlles, M.

AU - Page, C. P.

AU - Palange, P.

AU - Parr, D.

AU - Pistolesi, M.

AU - Rennard, S. I.

AU - Rutten-van Mölken, M. P.

AU - Stockley, R.

AU - Sullivan, S. D.

AU - Wedzicha, J. A.

AU - Wouters, E. F.

PY - 2008/2

Y1 - 2008/2

N2 - The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

AB - The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

UR - http://www.scopus.com/inward/record.url?scp=40649117704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40649117704&partnerID=8YFLogxK

U2 - 10.1183/09031936.00099306

DO - 10.1183/09031936.00099306

M3 - Review article

C2 - 18238951

AN - SCOPUS:40649117704

SN - 0903-1936

VL - 31

SP - 416

EP - 468

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

ER -

Outcomes for COPD pharmacological trials: From lung function to biomarkers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this